JPMorgan upgraded Zymeworks (ZYME) to Overweight from Neutral with a price target of $18, up from $12 following last week’s research and development day. The firm left the event more confident in the company’s oncology and autoimmune diseases pipeline. With partnered Ziihera “providing a solid support to the valuation, 2025 is the year investors should pay attention for Zymeworks, the analyst tells investors in a research note. The firm says the company could begin to see one or more of its “5×5” plan succeeding in the clinics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME: